Enjoy complimentary customisation on priority with our Enterprise License!
This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that is available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.
Technavio's report, the global congestive heart failure drugs market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the global congestive heart failure drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, a beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.
CHF drugs market size by regions
• Americas
• APAC
• EMEA
Congestive heart failure drugs market Vendors
• AstraZeneca
• Bristol-Myers Squibb
• GSK
• Merck & Co.
• Mylan
• Novartis
• Pfizer
• Sanofi
• Valeant Pharmaceuticals
Congestive heart failure drugs market driver
• Increase in Aging Population
• For a full, detailed list, view our report
CHF drugs market challenge
• Weak Pipeline
• For a full, detailed list, view our report
Congestive heart failure drugs market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Therapeutic Class
08. Late Stage Pipeline Molecules
09. Geographical Segmentation
09.1 Congestive Heart Failure Drugs Market in Americas
09.1.1 Market Size and Forecast
09.2 Congestive Heart Failure Drugs Market in Europe
09.2.1 Market Size and Forecast
09.3 Congestive Heart Failure Drugs Market in Asia
09.3.1 Market Size and Forecast
09.4 Congestive Heart Failure Drugs Market in ROW
09.4.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 AstraZeneca plc
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue 2013
18.1.4 Business Segmentation by Revenue 2011-2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Developments
18.1.8 SWOT Analysis
18.2 Bristol-Myers Squibb Co.
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Key Product Offerings
18.2.4 Revenue by Geography
18.2.5 Business Strategy
18.2.6 Key Information
18.2.7 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Sales by Geography
18.3.6 Pipeline Products
18.3.7 Business Strategy
18.3.8 Key Information
18.3.9 SWOT Analysis
18.4 Merck & Co. Inc.
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2013
18.4.4 Business Segmentation by Revenue 2012 and 2013
18.4.5 Sales by Geography
18.4.6 Business Strategy
18.4.7 Key Developments
18.4.8 SWOT Analysis
18.5 Mylan
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2011-2013
18.5.5 Geographical Segmentation by Revenue 2013
18.5.6 Business Strategy
18.5.7 Recent Developments
18.5.8 SWOT Analysis
18.6 Novartis AG
18.6.1 Key Facts
18.6.2 Business Description
18.6.3 Business Segmentation
18.6.4 Revenue by Business Segmentation
18.6.5 Revenue Comparison 2012 and 2013
18.6.6 Sales by Geography
18.6.7 Business Strategy
18.6.8 Key Developments
18.6.9 SWOT Analysis
18.7 Pfizer
18.7.1 Key Facts
18.7.2 Business Overview
18.7.3 Business Segmentation by Revenue 2013
18.7.4 Business Segmentation by Revenue 2012 and 2013
18.7.5 Geographical Segmentation by Revenue
18.7.6 Business Strategy
18.7.7 Key Developments
18.7.8 SWOT Analysis
18.8 Sanofi SA
18.8.1 Key Facts
18.8.2 Business Description
18.8.3 Business Segmentation
18.8.4 Revenue by Business Segmentation
18.8.5 Revenue Comparison 2012 and 2013
18.8.6 Sales by Geography
18.8.7 Business Strategy
18.8.8 Key Developments
18.8.9 SWOT Analysis
18.9 Valeant Pharmaceuticals International
18.9.1 Key Facts
18.9.2 Business Overview
18.9.3 Business Segmentation by Revenue 2013
18.9.4 Business Segmentation by Revenue 2012 and 2013
18.9.5 Sales by Geography
18.9.6 Business Strategy
18.9.7 Key Developments
18.9.8 SWOT Analysis
19. Other Reports in this Series
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
